Skip to main content
DTIL
NASDAQ Life Sciences

Precision BioSciences Q3 Loss Narrows to $7.6M on Warrant Gain; Cash Runway Through 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.912
Mkt Cap
$191.831M
52W Low
$3.53
52W High
$9.62
52W Position info
124% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

DTIL has more than doubled off its 52-week low of $3.53.

Summary

Precision BioSciences' Q3 net loss narrowed to $7.6M from $21.8M on a $12.7M non-cash warrant remeasurement gain, with $108.0M of cash and management-guided runway through 2028.


Key Events · Earnings and Guidance · DTIL

  • Q3 Loss Narrows on Non-Cash Warrant Gain

    Net loss was $7.6M versus $21.8M a year ago, driven by a $12.7M non-cash gain on warrant liability remeasurement; the operating loss was roughly flat at $20.4M versus $20.7M.

  • Cash Runway Extended Through 2028

    Cash, cash equivalents and restricted cash totaled $108.0M at September 30, 2026, which management says funds operations and the PBGENE-HBV and PBGENE-DMD data milestones through 2028.

  • ATM Funds the Quarter

    The company sold 1,408,833 shares through its ATM for $10.9M of net proceeds in Q3 2026, and $10.9M for the nine months, continuing dilution-based funding.

  • Nine-Month Revenue Jumps to $10.8M

    Revenue rose to $10.8M from $0.1M a year ago, driven by $6.8M recognized under the TG Therapeutics license milestone and $4.0M from a legacy agriculture license.


Analysis · DTIL · Life Sciences

The headline improvement is accounting, not operating: a $12.7M non-cash gain on warrant liability remeasurement cut the Q3 net loss to $7.6M from $21.8M a year ago, while the operating loss was essentially flat at $20.4M. What matters for the thesis is the balance sheet — $108.0M of cash, cash equivalents and restricted cash, with management stating runway through 2028, which covers the PBGENE-HBV and PBGENE-DMD clinical data milestones. The company is still funding itself through the ATM ($10.9M raised in Q3) and carries a $22.5M Banc of California term loan secured by a cash account that must hold at least the outstanding principal.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DTIL was trading at $7.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.8M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DTIL - Latest Insights

DTIL
Nov 05, 2026, 7:10 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.73
Real-time Price: $7.05 info
Change: -$0.680 (-9%) info
Market Cap: $196.947M info
DTIL
Nov 05, 2026, 7:07 AM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $7.05 info
Change: -$1.45 (-17%) info
Market Cap: $196.947M info
DTIL
Nov 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.05 info
Change: -$1.34 (-16%) info
Market Cap: $196.947M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.57
Real-time Price: $7.05 info
Change: -$1.52 (-18%) info
Market Cap: $196.947M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.05 info
Change: -$1.34 (-16%) info
Market Cap: $196.947M info